Caterina Musolino
A5046416905- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- Bone health and treatments
- Bone and Joint Diseases
- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Immune Cell Function and Interaction
- Kruppel-like factors research
- Platelet Disorders and Treatments
- Hematopoietic Stem Cell Transplantation
- MicroRNA in disease regulation
- Immunotherapy and Immune Responses
- Viral-associated cancers and disorders
- Cell Adhesion Molecules Research
- Cancer-related molecular mechanisms research
University of Messina
2014-2024
Azienda Ospedaliera Universitaria Policlinico "G. Martino"
2012-2023
Policlinico Universitario di Catania
1990-2022
Istituto Ortopedico Gaetano Pini
2021
Fondazione Gimema Onlus
2009-2020
National Institutes of Health
2019
Howard Hughes Medical Institute
2019
Wellcome Trust
2019
National Medical Research Center of Dentistry and Maxillofacial Surgery
2016
University of Bologna
2016
Current treatment recommendations for patients with polycythemia vera call maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in randomized clinical trial.We randomly assigned 365 adults JAK2-positive who were being treated phlebotomy, hydroxyurea, or both to receive either more intensive (target hematocrit, <45%) (low-hematocrit group) 45 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular...
Summary Givinostat, a histone‐deacetylase inhibitor ( HDAC i), inhibits proliferation of cells bearing the JAK 2 V617F mutation and has shown significant activity with good tolerability in patients chronic myeloproliferative neoplasms MPN ). In this multicentre, open‐label, phase II study, 44 polycythaemia vera PV ), unresponsive to maximum tolerated doses MTD ) hydroxycarbamide HC were treated Givinostat (50 or 100 mg/d) combination . The European LeukaemiaNet response criteria used assess...
Abstract We retrospectively studied 181 patients with polycythaemia vera ( n =67), essential thrombocythaemia =67) or primary myelofibrosis =47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd–Chiari syndrome (BCS) and portal were diagnosed in 31 (17.1%) 109 (60.3%) patients, respectively; isolated the mesenteric splenic veins was detected 18 23 cases, respectively. After this index event, followed for 735 patient years (pt-years) experienced recurrences...
Abstract Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival CML patients has become very close to normal. The next, ambitious, step is bring as many possible into a condition treatment-free remission (TFR). Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA; Italian Group for Hematologic Diseases Adult) Working Party (WP) developed project aimed at...
BackgroundWhether phlebotomy alone can adequately maintain target hematocrit in patients with low-risk polycythemia vera (PV) remains elusive.MethodsIn a phase 2 open-label randomized trial, we compared ropeginterferon alfa-2b (ropeg; 100 μg every weeks) only regarding maintenance of median level (≤45%) over 12 months the absence progressive disease (primary end point). In follow-up, crossover to alternative treatment group was allowed if primary point not met.ResultsIn total, 127 were...
The chronic lymphocytic leukemia International Prognostic Index (CLL‐IPI) combines 5 parameters (age, clinical stage, TP53 status [normal vs. del(17p) and/or mutation], IGHV mutational status, serum β2‐microglobulin) to predict survival and time‐to‐first‐treatment (TTFT) in CLL patients. We performed an observational study 337 prospectively collected, Binet stage A patients validate the ability of CLL‐IPI TTFT independent cohort early score stratified into three subgroups with different...